B ackground: Only 20% of patients with stage III NSCLC are cured by surgery. There is a disagreement among the oncologists in terms of whether which regimen (induction chemotherapy followed chemoradiotherapy, concurrent chemoradiation or concurrent chemoradiation followed consolidation chemotherapy) is best choice in inoperable LA NSCLC. Objective: To evaluate chemotherapy timing in inoperable LA NSCLC (before, only concomitant or after curative chemotherapy). Materials and methods: Total of 74 consecutive patient with LA NSCLC which was inoperable due to medical condition or stage from Kayseri Research and Training Hospital were analyzed retrospectively. The patients were divided into three groups according to treatment protocols: Induction chemotherapy followed chemoradiotherapy (Ind. CTàCRT), chemoradiotherapy (CRT) and chemoradiotherapy followed consolidation chemotherapy (CRTàCons. CT).. Results: When evaluating progression free survival (PFS), PFS did not significantly differed among the groups (p=0,078). We found significant difference among groups (p=0.047) in terms of overall survival. While CRTàCons. CT arm had highest mean and median survival times, Ind. CTàCRT arm had worst OS. Conclusions: CRTàCons. CT treatment modality seems preferable regimen for treatment of inoperable LA NSCLC.
INTRODUCTION
It is widely known that lung cancer is the leading cause of cancer related deaths in worldwide (1) . Approximately 80% of newly diagnosed lung cancers are non small cell lung cancer (NSCLC). Of patients with NSCLC 35 % are locally advanced at the time of diagnosis. According to the 7th edition of Tumor, Node, Metastasis (TNM) in lung cancer, locally advanced NSCLC (LA NSCLC) consists of stage III A (T1a,b T2 a,b N2M0 / T3N1,2M0 / T4N0,1M0) and IIIB (T4N2M0 / T any N3M0) disease (2) . Considering LA NSCLC only 20% of patients with stage III are cured by surgery. Therefore there is a disagreement among the oncologists in terms of whether surgery is necessary for treatment of LA NSCLC or not. In order to improve the outcomes of the locally advanced NSCLC, induction chemotherapy followed chemoradiotherapy (3, 4) , concurrent chemoradiation (5, 6, 7), concurrent chemoradiation followed consolidation chemotherapy (4, 7, 8, 9) have been investigated. However the optimal treatment regimen of patients with LA NSCLC (especially inoperable disease) has not been still defined.
In previously phase III randomized controlled studies, it was seen that the median survival duration was significantly superior in patients receiving concurrent therapy (16.5 months), as compared with those receiving sequential therapy (13.3 months) and concurrent cisplatin-based chemoradiotherapy confers a long-term survival benefit compared with the sequential chemotherapy followed radiotherapy (5, 6) . And in the other studies it was found similar results (7, 10, 11, 12) . In a study that compared induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy, it was reported that the addition of induction chemotherapy to concurrent chemoradiotherapy added toxicity and provided no survival benefit over concurrent chemoradiotherapy alone (3). In addition it was previously seen that induction chemotherapy followed radiotherapy provided a prolongation of median survival times over radiotherapy (13, 14, 15) . Some studies investigated concurrent chemoradiotherapy followed consolidation chemotherapy treatment modality. In a study, it was reported than chemoradiotherapy followed by con-
The Optimal Chemotherapy Timing in Patients with Inoperable Locally advanced Non small Cell Lung Cancer solidation chemotherapy seems to be associated with the best outcome according to sequential chemotherapy or induction fallowed chemoradiotherapy but it was mentioned that this schedule was associated with greater toxicity (9) . A other study was found that consolidation docetaxel after CRT did not improve survival in LA-NSCLC (16) .
In current study, we aimed to evaluate chemotherapy timing for treatment of patients with inoperable LA NSCLC according to medical condition and stage (before, only concomitant or after curative chemotherapy).
MeTHODS
The patients diagnosed with locally advanced NSCLC from Kayseri Research and Training Hospital were included in this study. Between the years 2006-2011, total of 74 consecutive patients who were stage III and inoperable according to staging or medical condition were analyzed using hospital records retrospectively. The patients were divided into three groups according to treatment protocols: Induction chemotherapy followed chemoradiotherapy (Ind. CTàCRT), chemoradiotherapy (CRT) and chemoradiotherapy followed consolidation chemotherapy (CRTàCons. CT). Staging was made according to the 6th or 7th version of TNM lung cancer staging system. Age, gender, histological subtypes of cancer, comorbidity and smoking status (current or former smoker) were recorded to Statistical Package for the Social Sciences 16.0 (SPSS16.0) statistical software for analysis.
Descriptive tests, chi square, independent-samples tests and survival analyses were performed for analysis. Survival time was estimated by the Kaplan-Meier method and the survival difference between groups was assessed by the log-rank test. P <0.05 was considered as a significant statistic.
ReSULTS
Of 74 patients, 22% was in Ind. CT-CRT arm, 44% was in CRT arm and 34% was in CRTàCons. CT. The characteristics of patients were given in Table 1 . For mean age of patients, there was a significant difference between CRT and CRTàCons.CT arms (p=0.001). However, there was no significant difference regarding sex (p=0.057), histology of cancer (p=0.961), comorbidity (p=0.396) a nd smok i ng st at u s (p=0.561).
When we evaluated the groups in terms of progression free survival (PFS), PFS did not significantly differed among the groups (p=0.078). The mean and median PFS were 6.56±1.66 and 5.00±1.57 months, 11.61±2.53 and 5.09±2.73 months and 11.82±1.46 and 9.52±1.67 months for Ind. CTàCRT, CRT and CRTàCons.CT arms, respectively. PFS were depicted in Table 2 and was shown in Figure 1 .
Considering overall survival (OS), we found significant difference among groups (p=0.047). While CRTàCons. CT arm had highest mean and median survival times, Ind. CTàCRT arm had worst OS. The mean and median OS were 9.93±1.85 and 8.77±1.24 months, 18.8±23.42 and 9.10±2.49 months and 20.8±83.23 and 16.6±52.70 months for Ind. CTàCRT, CRT and CRTàCons. CT arms, respectively. OS were given in Table 3 . And OS curves were shown in Figure 2. 
DISCUSSION
In presented study, we compared Ind. CTàCRT, CRT and CRTàCons.
CT treatment modalities in inoperable LA NSCLC and we evaluated that when chemotherapy can be preferred according to chemoradiotherapy.
Our results revealed that CRTàCons.CT treatment modality had best outcome in inoperable LA NSCLC in terms of overall survival. Interestingly CRT treatment modality results were better than Ind. CTàCRT arm. When evaluating PFS, Table 3 . Groups and overall survival results (p=0.047).
Figure 1. Progression free survival curves
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CRTàCons. CT had better median PFS time than Ind. CTàCRT and CRT treatment modalities but we did not found significantly difference. In a result, in addition to chemoradiotherapy that was the main treatment modality in patients with inoperable LA NSCLC, the timing of chemotherapy remains still controversial.
CONCLUSION
We can recommend that CRTà-Cons. CT is best treatment modality in younger and fit patients with inoperable LA NSCLC. Except for those patients CRT or only RT treatment modalities may be preferred.
